ERBB2 and breast cancer: To extend our investigation of the efficacy of the human version of the lead anti-HER2 IgE 26, we sought to explore anti-tumor activity in a human breast cancer xenograft model, known to be resistant to the Fab-mediated effects of Trastuzumab [8, 9, 33].